Figure 3.

Impact of DC-based vaccines therapy on tumor growth. (a) The C57BL/6 female mice were subcutaneously (s.c.) inoculated in the right flank with MC38 colon carcinoma cells (1.1 × 10⁶ cells/mouse, day 0). On the 15th and 22nd days, mice with established tumors were administered peritumorally (p.t.) with DCs genetically modified for IL-12 and IL-18 coproduction (DC/IL-18/TAg, DC/IL-12/TAg, DC/IL-18 + IL-12/TAg), stimulated with MC38 tumor cell lysate (2 × 10⁶ cells/mice) or control cells (DC/TAg, DC/EGFP/TAg). On the 29th day, the therapeutic effect of the administration of vaccines was determined. (b) Graph presenting median tumor volume after immunotherapy. (c) Table presenting statistically significant differences between groups after immunotherapy. (d) Box graph presenting median tumor volume, calculated on the 29th day of the experiment. (e) Table presenting MC38 tumor growth inhibition (TGI) calculated on 29th day of experiment in relation to the MC38 ctrl group. Results are presented as mean ± SD calculated for 10-13 mice per group. Differences between groups were estimated using the nonparametric Kruskal-Wallis test followed by Dunn's multiple comparison post hoc test.